[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kodiak Sciences Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100649457","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-tabirafusp-tedromer-compared-to-aflibercept-in-participants-with-dme---alto-100649457",false,"NCT07734844","A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO","A Randomized, Double-masked, Active-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Tedromer 5 mg Compared With Intravitreal Aflibercept 2 mg in Participants With Visual Impairment Secondary to Diabetic Macular Edema (DME) - ALTO","ALTO","Inclusion Criteria:\n\n* DME, treatment-naïve or previously-treated\n* Male or female ≥18 years of age with Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%\n* Capable of giving informed signed consent\n\nExclusion Criteria:\n\n* Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.\n* Current or history of retinal detachment (tractional or rhegmatogenous) in the Study Eye","ALL","18 Years",{"count":20,"type":21},910,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO",[27],"Diabetic Macular Edema (DME)",[29,30,31,32,33,34,35,36],"DME","KSI-501","tabirafusp tedromer","aflibercept","antibody biopolymer conjugate","anti-VEGF","anti-IL-6","Kodiak Sciences","RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-21","ACTUAL",{"date":43,"type":41},"2026-08-03",{"date":45,"type":21},"2029-09",{"name":47,"class":48},"Kodiak Sciences Inc","INDUSTRY",9,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100592642","phase-3-a-phase-3-study-to-evaluate-the-efficacy-and-safety-of-intravitreal-ksi-101-in-participants-with-macular-edema-secondary-to-inflammation-mesi---pinnacle-100592642","NCT06996080","A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE","A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE","PINNACLE","Inclusion Criteria:\n\n* Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥320 and \\\u003C400 microns on SD-OCT and a BCVA score of ≥25 and ≤78 ETDRS letters (between \\~20\u002F25 and 20\u002F320 Snellen equivalent) in the Study Eye.\n* Definitive presence of Intraretinal Fluid and\u002For Subretinal Fluid on SD-OCT in the Study Eye.\n* Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.\n\nExclusion Criteria:\n\n* ME in the Study Eye secondary to diabetes, RVO, or wAMD.\n* Active or suspected ocular or periocular infection in either eye.\n* Any history of or active occlusive retinal vasculitis in either eye.",{"count":59,"type":21},300,[24],"A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)",[63],"Macular Edema Secondary to Inflammation",[65,66,67,68],"MESI","macular edema","inflammatory macular edema","macular edema associated with inflammation","2026-05-14",{"date":71,"type":41},"2026-05-18",{"date":73,"type":41},"2025-07-16",{"date":75,"type":21},"2027-08",{"name":47,"class":48},56,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":61,"conditions":89,"keywords":90,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":77},"100592205","phase-3-a-phase-3-study-to-evaluate-the-efficacy-and-safety-of-intravitreal-ksi-101-in-participants-with-macular-edema-secondary-to-inflammation-mesi---peak-100592205","NCT06990399","A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK","PEAK","Inclusion Criteria:\n\n* Macular Edema Secondary to Inflammation (MESI) with a central subfield thickness (CST) of ≥400 microns on SD-OCT in Study Eye.\n* Definitive presence of Intraretinal Fluid and\u002For Subretinal Fluid on SD-OCT in the Study Eye.\n* BCVA ETDRS score of ≥25 and ≤70 letters (between 20\u002F40 and 20\u002F320 Snellen equivalent) in the Study Eye.\n* Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic in the Study Eye.\n\nExclusion Criteria:\n\n* Macular Edema in the Study Eye secondary to diabetic retinopathy, RVO, or wAMD.\n* Active or suspected ocular or periocular infection in either eye.\n* Any history of or active occlusive retinal vasculitis in either eye.",{"count":87,"type":21},600,[24],[63],[65,66,67,68],{"date":71,"type":41},{"date":93,"type":41},"2025-07-30",{"date":95,"type":21},"2027-11",{"name":47,"class":48},""]